eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, has opened a subsidiary, eTheRNA Asia, with offices located in the Sheung Wan area of Hong Kong.
The Asia-Pacific region is growing in importance in the global healthcare sector and this new subsidiary will serve as a focus for eTheRNA’s increasing commercial activities there. In particular, eTheRNA Asia will focus on supporting business and investor relations in China and especially the relationship between eTheRNA and its strategic partner, China Grand Pharmaceutical and Healthcare Holdings.
Steven Powell, Chief Executive Officer of eTheRNA, said: “The strategic aim under the Healthy China 2030 plan is to improve cancer care and develop truly innovative oncology drugs in China itself. Through our Chinese investors and partners we have developed strong links with the region and look forward to increasing our activities and contributing to help fulfil this ambition.”
